-- Draganfly（DPRO.CN，DPRO）週四宣布，已與ACSL簽署獨家總代理協議，並啟動技術整合。 該公司在一份聲明中表示：“此次合作將把ACSL的技術引入加拿大市場，同時，雙方的合作將推動兩家公司無人機平台之間令人興奮的新功能開發和互操作性提升。” 身為ACSL在加拿大的專屬合作夥伴，Draganfly將把ACSL SOTEN推向市場。 SOTEN是一款緊湊、易於部署的多任務平台，配備可更換有效載荷和安全設計架構。透過技術集成，Draganfly生產的某些無人機，例如Apex和Commander 3XL，將相容於SOTEN的可更換相機有效載荷以及ACSL TAITEN智慧控制器。 SOTEN平台將於2026年6月起在加拿大獨家透過Draganfly銷售。 該公司股票在加拿大證券交易所的最新報收在7.30加元，下跌0.1%。
Price: $7.30, Change: $-0.01, Percent Change: -0.14%
CVS Health (CVS) is increasingly more likely to reach its 3% Medicare Advantage target margin in 2028, RBC Capital Markets analyst said in a note Wednesday.Analysts said the company's Q1 adjusted earnings "comfortably" beat expectations, driven by "strong" topline growth and a notable improvement in profitability in the Health Care Benefits segment.Medical costs came in below expectations and, while the company maintained its medical benefit ratio guidance for the year, it is increasingly likely to outperform, according to the note.The brokerage raised its 2026 adjusted earnings estimate for the company to $7.41 from $7.10. Analysts surveyed by FactSet expect $7.29.RBC reiterated its outperform rating on the stock and increased its price target to $107 from $93.Price: $87.01, Change: $+0.14, Percent Change: +0.17%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We increase our target price to $86, from 85, on a forward P/E of 21x our 2027 EPS projection of $4.08, below historical averages. We increase our 2026 EPS projection to $3.59 from $3.52, and lift our 2027 EPS estimate to $4.08 from $4.06. TRMB reported solid Q1 beats with revenue of $939.9M, up 12% Y/Y, led by AECO at 14% organic revenue and ARR growth, Field Systems posting 12% growth, and Transportation & Logistics growing 7% despite freight market headwinds. ARR reached a record $2.435B, up 13% organically, reinforcing business model durability. Non-GAAP operating margin improved 230 bps to 25.9%, while non-GAAP gross margins expanded 180 bps to 71.0%, and we see continued margin expansion as its subscription revenues scale. We note steady execution in its core business, while building AI momentum through new products and partnerships with AI labs. Management reaffirmed its 2027 targets, supporting our positive view, though macro risks warrant monitoring.
Apollo Global Management (APO) shares are trading in-line with historical average multiple and at a lower discount against its peers, RBC Capital Markets said in a Thursday note."We maintain our Sector Perform rating largely driven by relative valuation," the report said.The note said its Q1 performance was characterized by strong fee-related earnings growth, offset by weak spread-related earnings growth, driving a low adjusted net income per share growth.RBC raised its price target to $146 from $139 on rolling forward its valuation and higher estimates.Price: $127.33, Change: $-2.20, Percent Change: -1.70%